Proposed Data Collection Submitted for Public Comment and Recommendations, 51429-51430 [2022-17990]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 161 / Monday, August 22, 2022 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–22–1279; Docket No. CDC–2022–
0093]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
an existing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on an existing information
collection project titled WISEWOMAN
National Program Evaluation. The goal
of the study is to assess the
implementation of the WISEWOMAN
program under the current cooperative
agreement and measure the effect of the
program on individual, organizational,
and community-level outcomes.
DATES: CDC must receive written
comments on or before October 21,
2022.
SUMMARY:
You may submit comments,
identified by Docket No. CDC–2022–
0093 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road, NE, MS
H21–8, Atlanta, Georgia 30329;
jspears on DSK121TN23PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
18:17 Aug 19, 2022
Jkt 256001
Telephone: 404–639–7118; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
WISEWOMAN National Program
Evaluation (OMB Control No. 0920–
1279, Exp. 12/31/2022)—Extension—
National Center for Chronic Disease
Prevention and Health Promotion
(NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The CDC has supported the
WISEWOMAN (Well-Integrated
Screening and Evaluation for Women
Across the Nation) program since 1995.
The WISEWOMAN program is designed
to serve low-income women ages 40–64
who have elevated risk factors for
cardiovascular disease (CVD) and have
no health insurance, or are
underinsured for medical and
PO 00000
Frm 00100
Fmt 4703
Sfmt 4703
51429
preventive care services. Through the
WISEWOMAN program, women have
access to screening services for selected
CVD risk factors such as elevated blood
cholesterol, hypertension, and abnormal
blood glucose levels; referrals to heathy
behavior support programs; and
referrals to medical care. WISEWOMAN
participants must be co-enrolled in the
CDC-sponsored National Breast and
Cervical Cancer Early Detection Program
(NBCCEDP).
The WISEWOMAN program is
administered through cooperative
agreements with state, territorial, or
tribal health departments. Each
WISEWOMAN recipient submits to CDC
an annual progress report that describes
program objectives and activities, and
semi-annual data reports (known as
minimum data elements, or MDEs) on
the screening, assessment, and healthy
behavior support services offered to
women who participate in the program.
Participant-level MDE are de-identified
prior to transmission to CDC.
In 2018, CDC released the fifth
funding opportunity announcement
(FOA) for the WISEWOMAN program
(DP18–1816), which resulted in fiveyear cooperative agreements with 24
state, territorial, and tribal health
departments, including six new and 18
continuing awardees from the previous
funding opportunity. Key program
elements were retained (e.g., provision
of screening services, promotion of
healthy lifestyle behaviors, and linkage
to healthy behavior support services and
community based resources), but a
number of changes were incorporated
into the program at that time. The
current FOA reflects increased emphasis
on three strategies to reduce CVD risk
and support hypertension control and
management, including: (1) tracking and
monitoring clinical measures; (2)
implementing team-based care; and (3)
linking community resources and
clinical services to support care
coordination, self-management, and
lifestyle change.
CDC seeks to conduct a multicomponent evaluation to assess the
effectiveness of the program on
individual, organizational, and
community-level outcomes. The indepth assessment is designed to
complement the routine progress and
MDE information already being
collected from WISEWOMAN program
recipients. The data collection focuses
on obtaining qualitative and
quantitative information at the
organizational and community levels
about process and procedures
implemented, and barriers, facilitators,
and other contextual factors that affect
program implementation and
E:\FR\FM\22AUN1.SGM
22AUN1
51430
Federal Register / Vol. 87, No. 161 / Monday, August 22, 2022 / Notices
participant outcomes. Data collection
activities include a Program Survey
with all WISEWOMAN awardee
programs, administered in the second
and fourth program years, and a onetime site visit to each recipient spread
across the three-year data collection
effort. During site visits, semi-structured
interviews will be conducted with
WISEWOMAN staff members and staff
at partner organizations, such as clinical
providers and community-based
resource providers, who are positioned
to provide a variety of perspectives on
program implementation.
OMB approval is requested for a oneyear Extension. CDC requests approval
for an estimated 84 annual burden
hours. Participation is voluntary and
there are no costs to respondents other
than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)
Total burden
(in hours)
Form name
WISEWOMAN Recipient Administrators.
Program survey ................................
16
1
1
16
Site Visit Discussion Guide ..............
Innovation Site Visit Discussion
Guide.
Site Visit Discussion Guide ..............
Innovation Site Visit Discussion
Guide.
Site Visit Discussion Guide ..............
Innovation Site Visit Discussion
Guide.
Site Visit Discussion Guide ..............
Innovation Site Visit Discussion
Guide.
8
2
1
1
90/60
45/60
12
2
16
2
1
1
1
45/60
16
2
16
2
1
1
1
45/60
16
2
16
2
1
1
1
45/60
16
2
........................
........................
........................
84
Recipient partners .............................
Healthy behavior support staff ..........
Clinical providers ...............................
Total ...........................................
...........................................................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–17990 Filed 8–19–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Appointment to the Board of Scientific
Counselors, National Center for Health
Statistics (BSC, NCHS)
ACTION:
Notice.
The Centers for Disease
Control and Prevention (CDC) is seeking
nominations for membership on the
Board of Scientific Counselors, National
Center for Health Statistics (BSC,
NCHS). The BSC, NCHS consists of up
to 15 experts including the Chair in
fields associated with statistical,
demographic, and epidemiological
research, such as biostatistics/biometry,
survey methodology and polling,
sociology, reproductive health, minority
health, nutrition, social and behavioral
health sciences, and population-based
public and environmental health; public
health practice, e.g., state and local
health data systems; operations
SUMMARY:
jspears on DSK121TN23PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Type of respondents
VerDate Sep<11>2014
18:17 Aug 19, 2022
Jkt 256001
research, health policy, and health
services research, including health
economics and econometrics; provision
of health services, e.g., medicine,
nursing, rehabilitation, other allied
health care, and preventive medicine;
health quality measurement and health
indicators; health promotion; medical
informatics; and data and health
information security, storage,
confidentiality, and dissemination.
DATES: Nominations for membership on
the BSC, NCHS must be received no
later than October 14, 2022. Packages
received after this time will not be
considered for the current membership
cycle.
ADDRESSES: All nominations should be
emailed to NCHS-BSCmail@cdc.gov.
FOR FURTHER INFORMATION CONTACT:
Rebecca Hines, M.H.S., Designated
Federal Officer, Board of Scientific
Counselors, NCHS, CDC, 3311 Toledo
Road, Mailstop P–08, Hyattsville,
Maryland 20782; Telephone: (301) 458–
4715; Email: RSHines@cdc.gov.
SUPPLEMENTARY INFORMATION:
Nominations are being sought for
individuals who have the expertise and
qualifications necessary to contribute to
the accomplishment of the Board’s
objective to provide advice and
guidance on statistical and
epidemiological research, data
collection, and activities that support
the National Center for Health Statistics,
PO 00000
Frm 00101
Fmt 4703
Sfmt 4703
such as: determinants of health; extent
and nature of illness and disability,
including life expectancy; incidence of
various acute and chronic illnesses/
impairments and accidental injuries;
prevalence of chronic diseases and
impairments; infant and maternal
morbidity and mortality; nutrition
status; environmental, social, and other
hazards affecting health status; health
resources associated with physician and
dental visits, hospitalizations, nursing,
extended care facilities, home health
agencies, and other health institutions;
utilization of health care in a broad
array of settings; trends in prices/costs
and sources of payments; federal, state,
and local government expenditures for
health care services; the relationship
between demographic and
socioeconomic characteristics and
health characteristics; family formation,
growth, and dissolution; new or
improved methods for obtaining current
data on the aforementioned factors; data
security and confidentiality and
comparability of data; and standardized
means to collect information and
statistics.
Additionally, the Board makes
recommendations about opportunities
for NCHS programs to examine and
employ new approaches to monitoring
and evaluating key public health, health
policy, and public policy changes. This
includes automation, data
modernization, and technological
E:\FR\FM\22AUN1.SGM
22AUN1
]]>Agencies
[Federal Register Volume 87, Number 161 (Monday, August 22, 2022)]
[Notices]
[Pages 51429-51430]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17990]
[[Page 51429]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-22-1279; Docket No. CDC-2022-0093]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on an existing information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on an existing information collection project
titled WISEWOMAN National Program Evaluation. The goal of the study is
to assess the implementation of the WISEWOMAN program under the current
cooperative agreement and measure the effect of the program on
individual, organizational, and community-level outcomes.
DATES: CDC must receive written comments on or before October 21, 2022.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2022-
0093 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (www.regulations.gov) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road, NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7118;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
WISEWOMAN National Program Evaluation (OMB Control No. 0920-1279,
Exp. 12/31/2022)--Extension--National Center for Chronic Disease
Prevention and Health Promotion (NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The CDC has supported the WISEWOMAN (Well-Integrated Screening and
Evaluation for Women Across the Nation) program since 1995. The
WISEWOMAN program is designed to serve low-income women ages 40-64 who
have elevated risk factors for cardiovascular disease (CVD) and have no
health insurance, or are underinsured for medical and preventive care
services. Through the WISEWOMAN program, women have access to screening
services for selected CVD risk factors such as elevated blood
cholesterol, hypertension, and abnormal blood glucose levels; referrals
to heathy behavior support programs; and referrals to medical care.
WISEWOMAN participants must be co-enrolled in the CDC-sponsored
National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
The WISEWOMAN program is administered through cooperative
agreements with state, territorial, or tribal health departments. Each
WISEWOMAN recipient submits to CDC an annual progress report that
describes program objectives and activities, and semi-annual data
reports (known as minimum data elements, or MDEs) on the screening,
assessment, and healthy behavior support services offered to women who
participate in the program. Participant-level MDE are de-identified
prior to transmission to CDC.
In 2018, CDC released the fifth funding opportunity announcement
(FOA) for the WISEWOMAN program (DP18-1816), which resulted in five-
year cooperative agreements with 24 state, territorial, and tribal
health departments, including six new and 18 continuing awardees from
the previous funding opportunity. Key program elements were retained
(e.g., provision of screening services, promotion of healthy lifestyle
behaviors, and linkage to healthy behavior support services and
community based resources), but a number of changes were incorporated
into the program at that time. The current FOA reflects increased
emphasis on three strategies to reduce CVD risk and support
hypertension control and management, including: (1) tracking and
monitoring clinical measures; (2) implementing team-based care; and (3)
linking community resources and clinical services to support care
coordination, self-management, and lifestyle change.
CDC seeks to conduct a multi-component evaluation to assess the
effectiveness of the program on individual, organizational, and
community-level outcomes. The in-depth assessment is designed to
complement the routine progress and MDE information already being
collected from WISEWOMAN program recipients. The data collection
focuses on obtaining qualitative and quantitative information at the
organizational and community levels about process and procedures
implemented, and barriers, facilitators, and other contextual factors
that affect program implementation and
[[Page 51430]]
participant outcomes. Data collection activities include a Program
Survey with all WISEWOMAN awardee programs, administered in the second
and fourth program years, and a one-time site visit to each recipient
spread across the three-year data collection effort. During site
visits, semi-structured interviews will be conducted with WISEWOMAN
staff members and staff at partner organizations, such as clinical
providers and community-based resource providers, who are positioned to
provide a variety of perspectives on program implementation.
OMB approval is requested for a one-year Extension. CDC requests
approval for an estimated 84 annual burden hours. Participation is
voluntary and there are no costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
WISEWOMAN Recipient Program survey.. 16 1 1 16
Administrators.
Site Visit 8 1 90/60 12
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
Recipient partners............ Site Visit 16 1 1 16
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
Healthy behavior support staff Site Visit 16 1 1 16
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
Clinical providers............ Site Visit 16 1 1 16
Discussion
Guide.
Innovation Site 2 1 45/60 2
Visit
Discussion
Guide.
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 84
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2022-17990 Filed 8-19-22; 8:45 am]
BILLING CODE 4163-18-P
